Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evolving paradigms in thymoma surgery and multidisciplinary care: a narrative review.

Mediastinum (Hong Kong, China)·2026
Same author

Subclinical primary aldosteronism and major adverse cardiovascular events: evidence for a continuum of renin-independent aldosterone excess and a proposal for early detection.

Frontiers in cardiovascular medicine·2026
Same author

Revealing biomechanical vulnerabilities in oral cancer cells using 3D coculture platform and low-frequency ultrasound.

Materials today. Bio·2026
Same author

Dose-Response Relationships and Comparative Efficacy of Aldosterone Synthase Inhibitors in Resistant Hypertension: A Comprehensive Network Meta-Analysis and Meta-Regression.

Journal of clinical medicine·2026
Same author

Open, Hybrid and Endovascular Management of Aortic Arch Aneurysms: Recent Updates and Future Directions.

Journal of clinical medicine·2026
Same author

A round-robin exercise for the precise prediction of aqueous solubility of organic chemicals using chemometric, machine learning, and stacking ensemble of deep learning models.

Journal of computer-aided molecular design·2026

相关实验视频

Updated: Sep 10, 2025

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

9.8K

作为VEGFR-2抑制剂的1,3,4-提亚衍生物及其癌症治疗的分子洞察力

Pragya Gawande1, Balaji Wamanrao Matore1, Anjali Murmu1

  • 1Laboratory of Drug Discovery and Ecotoxicology, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.

Chemistry & biodiversity
|August 26, 2025
PubMed
概括

作为针对血管内皮生长因子受体-2 (VEGFR-2) 的新型抑制剂,1,3,4- 亚醇衍生物在癌症治疗中具有前景. 与现有治疗方法相比,这些化合物具有提高选择性和降低毒性的潜力.

关键词:
一,三,四-亚血管新生癌症结构活动关系 (SAR) 和机制血管内皮生长因子受体-2 (VEGFR-2) 抑制剂

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

相关实验视频

Last Updated: Sep 10, 2025

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

9.8K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

科学领域:

  • 癌症学
  • 医学化学
  • 分子生物学

背景情况:

  • 血管内皮生长因子受体-2 (VEGFR-2) 对瘤生长,血管生成和转移至关重要.
  • 目前的VEGFR-2抑制剂面临挑战,包括耐药性,毒性和缺乏选择性.
  • 1,3,4-thiadiazole (TDA) 支架为开发新的抗癌药物提供了一个有前途的结构.

研究的目的:

  • 审查VEGFR-2在癌症中的作用.
  • 探索1,3,4-TDA衍生物的化学和VEGFR-2抑制机制.
  • 分析结构-活性关系 (SAR) 并指导新型抑制剂的设计.

主要方法:

  • 在过去十年中发表的基于1,3,4-TDA的VEGFR-2抑制剂的系统文献综述.
  • 对151种TDA衍生物的分析,评估化学空间,SAR,选择性,毒性和结合相互作用.
  • 检查TDA支架的特定化学特征,这些特征有助于VEGFR-2结合.

主要成果:

  • 1,3,4-TDA衍生物具有显著的VEGFR-2抑制潜力.
  • 涉及TDA支架的基因和硫原子的关键分子相互作用对VEGFR-2结合至关重要.
  • 分析发现了影响抑制剂有效性和选择性的特定替代模式和SAR趋势.

结论:

  • 1,3,4-TDA衍生物为开发下一代VEGFR-2抑制剂提供了宝贵的支架.
  • 这些化合物为设计更有选择性,更少毒性的抗癌疗法提供了战略优势.
  • 对基于TDA的抑制剂的进一步研究可以带来更好的抗癌药物候选药物.